Recently Added Drugs

1. Alyftrek patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE50453 VERTEX PHARMS INC NA
May, 2027

(1 year, 9 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 20, 2029

Drugs and Companies using DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM ingredient

NCE-1 date: 20 December, 2028

Market Authorisation Date: 20 December, 2024

Treatment: NA

Dosage: TABLET

More Information on Dosage

ALYFTREK family patents

Family Patents

2. Annovera patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12303518 MAYNE PHARMA System for providing birth control
Jun, 2039

(13 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 10, 2023

Drugs and Companies using ETHINYL ESTRADIOL; SEGESTERONE ACETATE ingredient

NCE-1 date: 10 August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: NA

Dosage: RING

More Information on Dosage

ANNOVERA family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Arynta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11576878 AZURITY Oral solutions comprising lisdexamfetamine salts
Aug, 2040

(15 years from now)




Drugs and Companies using LISDEXAMFETAMINE DIMESYLATE ingredient

Market Authorisation Date: 16 June, 2025

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

ARYNTA family patents

Family Patents

4. Augtyro patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12310968 BRISTOL Chiral diaryl macrocycles and uses thereof
Jul, 2036

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 15, 2028
ODE*(ODE*) Nov 15, 2030
Orphan Drug Exclusivity(ODE-455) Nov 15, 2030
Orphan Drug Exclusivity(ODE-483) Jun 13, 2031
Orphan Drug Exclusivity(ODE-488) Jun 13, 2031

Drugs and Companies using REPOTRECTINIB ingredient

NCE-1 date: 16 November, 2027

Market Authorisation Date: 15 November, 2023

Treatment: Treatment of adult patients with locally advanced or metastatic ros1-positive non-small cell lung cancer (nsclc)

Dosage: CAPSULE

More Information on Dosage

AUGTYRO family patents

Family Patents

5. Avmapki Fakzynja Co-pack (copackaged) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7897792 VERASTEM INC Coumarin derivative having antitumor activity
Feb, 2027

(1 year, 6 months from now)

US8247411 VERASTEM INC Sulfonyl amide derivatives for the treatment of abnormal cell growth
Apr, 2028

(2 years from now)

US7928109 VERASTEM INC Sulfonyl amide derivatives for the treatment of abnormal cell growth
Aug, 2029

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11400090 VERASTEM INC Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder
Oct, 2038

(13 years from now)

US11517573 VERASTEM INC Therapeutic compositions, combinations, and methods of use
Sep, 2040

(15 years from now)

US11873296 VERASTEM INC Solid forms of a dual RAF/MEK inhibitor
Dec, 2042

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 08, 2030

Drugs and Companies using AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE ingredient

NCE-1 date: 08 May, 2029

Market Authorisation Date: 08 May, 2025

Treatment: Treatment of adult patients with kras-mutated recurrent low-grade serous ovarian cancer (lgsoc) who have received prior systemic therapy, in combination with defactinib; Treatment of adult patients wi...

Dosage: CAPSULE, TABLET

More Information on Dosage

AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) family patents

Family Patents

6. Barhemsys patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12329740 ACACIA Rescue treatment of post operative nausea and vomiting
Feb, 2038

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 26, 2025

Drugs and Companies using AMISULPRIDE ingredient

NCE-1 date: 27 February, 2024

Market Authorisation Date: 26 February, 2020

Treatment: Prevention and treatment of post-operative nausea and vomiting

Dosage: SOLUTION

More Information on Dosage

BARHEMSYS family patents

Family Patents

7. Brukinsa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9447106 BEONE MEDICINES USA Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators
Apr, 2034

(8 years from now)

US10927117 BEONE MEDICINES USA Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(12 years from now)

US11851437 BEONE MEDICINES USA Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10570139 BEONE MEDICINES USA Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Apr, 2034

(8 years from now)

US11142528 BEONE MEDICINES USA Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Apr, 2034

(8 years from now)

US11591340 BEONE MEDICINES USA Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(12 years from now)

US11884674 BEONE MEDICINES USA Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(12 years from now)

US11970500 BEONE MEDICINES USA Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)- 2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(12 years from now)

US11701357 BEONE MEDICINES USA Treatment of B cell cancers using a combination comprising Btk inhibitors
Jun, 2039

(13 years from now)

US12233069 BEONE MEDICINES USA Oral solid tablet comprising Bruton's Tyrosine Kinase inhibitor and preparation method therefor
Jun, 2040

(14 years from now)

US11786531 BEONE MEDICINES USA Methods of treating B-cell proliferative disorder
Jan, 2043

(17 years from now)

US11896596 BEONE MEDICINES USA Methods of treating B-cell proliferative disorder
Jan, 2043

(17 years from now)

US11911386 BEONE MEDICINES USA Methods of treating B-cell proliferative disorder
Jan, 2043

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-871) Aug 31, 2024
New Indication(I-874) Sep 14, 2024
New Chemical Entity Exclusivity(NCE) Nov 14, 2024
New Indication(I-817) Jan 19, 2026
Orphan Drug Exclusivity(ODE-276) Nov 14, 2026
New Indication(I-936) Mar 07, 2027
ODE*(ODE*) Aug 31, 2028
Orphan Drug Exclusivity(ODE-371) Aug 31, 2028
Orphan Drug Exclusivity(ODE-370) Sep 14, 2028
Orphan Drug Exclusivity(ODE-274) Jan 19, 2030
Orphan Drug Exclusivity(ODE-467) Mar 07, 2031

Drugs and Companies using ZANUBRUTINIB ingredient

Market Authorisation Date: 10 June, 2025

Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (s...

Dosage: TABLET

More Information on Dosage

BRUKINSA family patents

Family Patents

8. Crexont patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12303481 IMPAX Levodopa dosing regimen
Dec, 2041

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 07, 2027

Drugs and Companies using CARBIDOPA; LEVODOPA ingredient

Market Authorisation Date: 07 August, 2024

Treatment: Treatment of parkinsonism that may follow manganese intoxication

Dosage: CAPSULE, EXTENDED RELEASE

More Information on Dosage

CREXONT family patents

Family Patents

9. Epsolay patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12350382 MAYNE PHARMA NA
Feb, 2028

(2 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 22, 2025

Drugs and Companies using BENZOYL PEROXIDE ingredient

Market Authorisation Date: 22 April, 2022

Treatment: NA

Dosage: CREAM

More Information on Dosage

EPSOLAY family patents

Family Patents

10. Erleada patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12303493 JANSSEN BIOTECH Anticancer compositions
Dec, 2035

(10 years from now)

US12303497 JANSSEN BIOTECH Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
Jan, 2040

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-808) Sep 17, 2022
New Chemical Entity Exclusivity(NCE) Feb 14, 2023

Drugs and Companies using APALUTAMIDE ingredient

NCE-1 date: 14 February, 2022

Market Authorisation Date: 14 February, 2018

Treatment: Improvement of overall survival and progression free survival in metastatic, castration-resistant prostate cancer (mcrpc) patients by treatment with 240 mg oral apalutamide in combination with androge...

Dosage: TABLET

How can I launch a generic of ERLEADA before it's drug patent expiration?
More Information on Dosage

ERLEADA family patents

Family Patents

11. Gomekli patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12324791 SPRINGWORKS Mirdametinib treatment
Mar, 2043

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 11, 2030
Orphan Drug Exclusivity(ODE-488) Feb 11, 2032

Drugs and Companies using MIRDAMETINIB ingredient

NCE-1 date: 11 February, 2029

Market Authorisation Date: 11 February, 2025

Treatment: Treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic plexiform neurofibromas (pn) not amenable to complete resection

Dosage: CAPSULE

More Information on Dosage

GOMEKLI family patents

Family Patents

12. Ibtrozi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9187489 NUVATION Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
Jun, 2033

(7 years from now)

US9751887 NUVATION Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
Jun, 2033

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 11, 2030

Drugs and Companies using TALETRECTINIB ADIPATE ingredient

NCE-1 date: 11 June, 2029

Market Authorisation Date: 11 June, 2025

Treatment: Treatment of patients with locally advanced or metastatic ros1-positive non-small cell lung cancer (nsclc)

Dosage: CAPSULE

More Information on Dosage

IBTROZI family patents

Family Patents

13. Kalydeco patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8354427

(Pediatric)

VERTEX PHARMS Modulators of ATP-binding cassette transporters
Jan, 2027

(1 year, 5 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 31, 2017
New Indication(I-740) Feb 21, 2017
New Indication(I-705) Dec 30, 2017
Orphan Drug Exclusivity(ODE) Jan 31, 2019
Orphan Drug Exclusivity(ODE-20) Jan 31, 2019
New Patient Population(NPP) May 03, 2026
Orphan Drug Exclusivity(ODE-186) Feb 21, 2021
Orphan Drug Exclusivity(ODE-187) Dec 29, 2021
Orphan Drug Exclusivity(ODE-188) Mar 17, 2022
Orphan Drug Exclusivity(ODE-190) May 17, 2024
Orphan Drug Exclusivity(ODE-189) Jul 31, 2024
Orphan Drug Exclusivity(ODE-199) Aug 15, 2025
Orphan Drug Exclusivity(ODE-236) Apr 29, 2026
Pediatric Exclusivity(PED) Jun 21, 2028
Orphan Drug Exclusivity(ODE-338) Dec 21, 2027
Orphan Drug Exclusivity(ODE-435) May 03, 2030

Drugs and Companies using IVACAFTOR ingredient

NCE-1 date: 22 June, 2027

Market Authorisation Date: 20 May, 2019

Treatment: NA

Dosage: TABLET

How can I launch a generic of KALYDECO before it's drug patent expiration?
More Information on Dosage

KALYDECO family patents

Family Patents

14. Kalydeco patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8354427

(Pediatric)

VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Jan, 2027

(1 year, 5 months from now)

US10272046

(Pediatric)

VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Aug, 2033

(8 years from now)

US11147770

(Pediatric)

VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Aug, 2033

(8 years from now)

US11752106

(Pediatric)

VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Aug, 2033

(8 years from now)

US12214083

(Pediatric)

VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Aug, 2033

(8 years from now)

US8883206

(Pediatric)

VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Aug, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 31, 2017
New Indication(I-740) Feb 21, 2017
New Indication(I-705) Dec 30, 2017
Orphan Drug Exclusivity(ODE) Jan 31, 2019
Orphan Drug Exclusivity(ODE-20) Jan 31, 2019
New Patient Population(NPP) May 03, 2026
Orphan Drug Exclusivity(ODE-186) Feb 21, 2021
Orphan Drug Exclusivity(ODE-187) Dec 29, 2021
Orphan Drug Exclusivity(ODE-188) Mar 17, 2022
Orphan Drug Exclusivity(ODE-190) May 17, 2024
Orphan Drug Exclusivity(ODE-189) Jul 31, 2024
Orphan Drug Exclusivity(ODE-199) Aug 15, 2025
Orphan Drug Exclusivity(ODE-236) Apr 29, 2026
Pediatric Exclusivity(PED) Jun 21, 2028
Orphan Drug Exclusivity(ODE-338) Dec 21, 2027
Orphan Drug Exclusivity(ODE-435) May 03, 2030

Drugs and Companies using IVACAFTOR ingredient

NCE-1 date: 03 November, 2025

Market Authorisation Date: 03 May, 2023

Treatment: NA

Dosage: GRANULE

How can I launch a generic of KALYDECO before it's drug patent expiration?
More Information on Dosage

KALYDECO family patents

Family Patents

15. Katerzia patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12336984 AZURITY Amlodipine formulations
Oct, 2037

(12 years from now)




Drugs and Companies using AMLODIPINE BENZOATE ingredient

Market Authorisation Date: 08 July, 2019

Treatment: A method of treating hypertension

Dosage: SUSPENSION

How can I launch a generic of KATERZIA before it's drug patent expiration?
More Information on Dosage

KATERZIA family patents

Family Patents

16. Konvomep patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12329752 AZURITY Compositions and kits for omeprazole suspension
Jul, 2039

(13 years from now)




Drugs and Companies using OMEPRAZOLE; SODIUM BICARBONATE ingredient

Market Authorisation Date: 30 August, 2022

Treatment: NA

Dosage: FOR SUSPENSION

More Information on Dosage

KONVOMEP family patents

Family Patents

17. Koselugo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12318367 ASTRAZENECA Pharmaceutical composition
Mar, 2029

(3 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 10, 2025
Orphan Drug Exclusivity(ODE-288) Apr 10, 2027

Drugs and Companies using SELUMETINIB SULFATE ingredient

NCE-1 date: 10 April, 2024

Market Authorisation Date: 10 April, 2020

Treatment: NA

Dosage: CAPSULE

More Information on Dosage

KOSELUGO family patents

Family Patents

18. Myfembree patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US12325714 SUMITOMO PHARMA Compositions of thienopyrimidine derivatives
Sep, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 26, 2024
New Indication(I-898) Aug 05, 2025
New Chemical Entity Exclusivity(NCE) Dec 18, 2025
M(M-289) Jan 27, 2026

Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient

NCE-1 date: 18 December, 2024

Market Authorisation Date: 26 May, 2021

Treatment: NA

Dosage: TABLET

More Information on Dosage

MYFEMBREE family patents

Family Patents

19. Neffy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12324838 ARS PHARMS OPERATION Intranasal epinephrine formulations and methods for the treatment of disease
Feb, 2039

(13 years from now)




Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 05 March, 2025

Treatment: NA

Dosage: SPRAY

More Information on Dosage

NEFFY family patents

Family Patents

20. Nubeqa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12329742 BAYER HEALTHCARE Pharmaceutical composition of darolutamide
May, 2042

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 30, 2024
New Indication(I-900) Aug 05, 2025

Drugs and Companies using DAROLUTAMIDE ingredient

NCE-1 date: 31 July, 2023

Market Authorisation Date: 30 July, 2019

Treatment: NA

Dosage: TABLET

More Information on Dosage

NUBEQA family patents

Family Patents

21. Orgovyx patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US12325714 SUMITOMO PHARMA Compositions of thienopyrimidine derivatives
Sep, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12336990 SUMITOMO PHARMA Treatment of prostate cancer
Sep, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 18, 2025

Drugs and Companies using RELUGOLIX ingredient

NCE-1 date: 18 December, 2024

Market Authorisation Date: 18 December, 2020

Treatment: Treatment of adult patients with advanced prostate cancer

Dosage: TABLET

More Information on Dosage

ORGOVYX family patents

Family Patents

22. Ponvory patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12336980 VANDA PHARMS INC Dosing regimen for a selective S1P1 receptor agonist
Dec, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 18, 2026

Drugs and Companies using PONESIMOD ingredient

NCE-1 date: 18 March, 2025

Market Authorisation Date: 18 March, 2021

Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults using a dose titratio...

Dosage: TABLET

More Information on Dosage

PONVORY family patents

Family Patents

23. Purified Cortrophin Gel patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12324787 ANI PHARMS Contactless optical process for identifying objects
Oct, 2043

(18 years from now)




Drugs and Companies using CORTICOTROPIN ingredient

Market Authorisation Date: 01 January, 1982

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

PURIFIED CORTROPHIN GEL family patents

Family Patents

24. Radicava Ors patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12310946 MITSUBISHI TANABE Pharmaceutical composition for oral administration of edaravone and method of administering same
Nov, 2041

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 12, 2025
Orphan Drug Exclusivity(ODE-144) May 12, 2029

Drugs and Companies using EDARAVONE ingredient

Market Authorisation Date: 12 May, 2022

Treatment: Treatment of amyotrophic lateral sclerosis by administering a liquid edaravone composition relative to the timing and type of food consumption

Dosage: SUSPENSION

How can I launch a generic of RADICAVA ORS before it's drug patent expiration?
More Information on Dosage

RADICAVA ORS family patents

Family Patents

25. Relistor patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12303592 SALIX PHARMS Formulations for parenteral delivery of compounds and uses thereof
Aug, 2027

(2 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 24, 2013
New Product(NP) Jul 19, 2019

Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient

NCE-1 date: 24 April, 2012

Market Authorisation Date: 27 September, 2010

Treatment: Treatment of opioid-induced constipation (oic) in adults with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., ...

Dosage: SOLUTION

How can I launch a generic of RELISTOR before it's drug patent expiration?
More Information on Dosage

RELISTOR family patents

Family Patents

26. Ryaltris patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US12303635 GLENMARK SPECLT Dispensing device and pharmaceutical composition for the treatment of rhinitis
Apr, 2039

(13 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 13, 2025

Drugs and Companies using MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 13 January, 2022

Treatment: NA

Dosage: SPRAY, METERED

More Information on Dosage

RYALTRIS family patents

Family Patents

27. Symdeko (copackaged) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE50453 VERTEX PHARMS INC NA
May, 2027

(1 year, 9 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jun 21, 2022
New Chemical Entity Exclusivity(NCE) Feb 12, 2023
Orphan Drug Exclusivity(ODE-173) Feb 12, 2025
Orphan Drug Exclusivity(ODE-247) Jun 21, 2026
Orphan Drug Exclusivity(ODE-335) Dec 21, 2027

Drugs and Companies using IVACAFTOR; IVACAFTOR, TEZACAFTOR ingredient

NCE-1 date: 12 February, 2022

Market Authorisation Date: 21 June, 2019

Treatment: NA

Dosage: TABLET

More Information on Dosage

SYMDEKO (COPACKAGED) family patents

Family Patents

28. Tarpeyo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12311057 CALLIDITAS Pharmaceutical compositions
Jan, 2043

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 15, 2024
Orphan Drug Exclusivity(ODE-389) Dec 15, 2028
Orphan Drug Exclusivity(ODE-464) Dec 20, 2030

Drugs and Companies using BUDESONIDE ingredient

Market Authorisation Date: 15 December, 2021

Treatment: Treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression, by release of budesonide from the formulation

Dosage: CAPSULE, DELAYED RELEASE

More Information on Dosage

TARPEYO family patents

Family Patents

29. Tryptyr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028920 ALCON LABS INC Methods for treating occular irritation involving tearing by administering modulators of TRPM8
Sep, 2031

(6 years from now)

US9095609 ALCON LABS INC Ophthalmic composition comprising ws-12 and methods to treat xerophthalmia
Sep, 2031

(6 years from now)

US9433679 ALCON LABS INC Use of TRMP8 for treating opthalmic diseases or conditions involving tearing
Sep, 2031

(6 years from now)

US11850221 ALCON LABS INC Ophthalmic pharmaceutical compositions and uses thereof
Dec, 2042

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 28, 2030

Drugs and Companies using ACOLTREMON ingredient

NCE-1 date: 28 May, 2029

Market Authorisation Date: 28 May, 2025

Treatment: Treatment of the signs and symptoms of dry eye disease (ded)

Dosage: SOLUTION/DROPS

More Information on Dosage

TRYPTYR family patents

Family Patents

30. Tryvio patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12297189 IDORSIA Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan
Feb, 2038

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 22, 2029

Drugs and Companies using APROCITENTAN ingredient

NCE-1 date: 22 March, 2028

Market Authorisation Date: 19 March, 2024

Treatment: NA

Dosage: TABLET

More Information on Dosage

TRYVIO family patents

Family Patents

31. Ubrelvy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12310953 ABBVIE Pharmaceutical formulations for the treatment of migraine
Jan, 2035

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 23, 2024

Drugs and Companies using UBROGEPANT ingredient

NCE-1 date: 24 December, 2023

Market Authorisation Date: 23 December, 2019

Treatment: NA

Dosage: TABLET

More Information on Dosage

UBRELVY family patents

Family Patents

32. Valtoco patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12337061 NEURELIS INC Administration of benzodiazepine compositions
Jun, 2032

(6 years from now)

US12324852 NEURELIS INC Administration of benzodiazepine compositions
Oct, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 10, 2023
Orphan Drug Exclusivity(ODE-279) Jan 10, 2027
New Patient Population(NPP) Apr 15, 2028

Drugs and Companies using DIAZEPAM ingredient

Market Authorisation Date: 10 January, 2020

Treatment: Nasal administration of diazepam for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient's usual seizure pattern in patients with ep...

Dosage: SPRAY

More Information on Dosage

VALTOCO family patents

Family Patents

33. Vasostrict patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12186362 ENDO OPERATIONS Vasopressin formulations for use in treatment of hypotension
Jan, 2035

(9 years from now)




Drugs and Companies using VASOPRESSIN ingredient

Market Authorisation Date: 17 April, 2014

Treatment: NA

Dosage: SOLUTION

How can I launch a generic of VASOSTRICT before it's drug patent expiration?
More Information on Dosage

VASOSTRICT family patents

Family Patents

34. Vykat Xr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12343348 SOLENO THERAP Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
Nov, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 26, 2028

Drugs and Companies using DIAZOXIDE CHOLINE ingredient

Market Authorisation Date: 26 March, 2025

Treatment: Treating hyperphagia and reducing hyperphagic aggressive behaviors in prader-willi syndrome patients

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

VYKAT XR family patents

Family Patents

35. Widaplik patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10322117 GEORGE MEDICINES Compositions for the treatment of hypertension
Jan, 2038

(12 years from now)

US10799487 GEORGE MEDICINES Compositions for the treatment of hypertension
Jan, 2038

(12 years from now)




Drugs and Companies using AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN ingredient

Market Authorisation Date: 05 June, 2025

Treatment: A method of treating hypertension

Dosage: TABLET

More Information on Dosage

WIDAPLIK family patents

Family Patents

36. Xaciato patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12303563 ORGANON LLC Topical formulations and treatments
Sep, 2036

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 07, 2024
Generating Antibiotic Incentives Now(GAIN) Dec 07, 2029

Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient

Market Authorisation Date: 07 December, 2021

Treatment: NA

Dosage: GEL

More Information on Dosage

XACIATO family patents

Family Patents

37. Xofluza patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8987441 GENENTECH INC Substituted polycyclic carbamoyl pyridone derivative prodrug
Sep, 2031

(6 years from now)

US10392406 GENENTECH INC Substituted polycyclic pyridone derivatives and prodrugs thereof
Apr, 2036

(10 years from now)

US10759814 GENENTECH INC Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
Aug, 2037

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9815835 GENENTECH INC Substituted polycyclic carbamolypyridone derivative
Jun, 2030

(4 years from now)

US8927710 GENENTECH INC Substituted polycyclic carbamoylpyridone derivative
May, 2031

(5 years from now)

US10633397 GENENTECH INC Substituted polycyclic pyridone derivatives and prodrugs thereof
Apr, 2036

(10 years from now)

US11306106 GENENTECH INC Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
Aug, 2037

(12 years from now)

US11261198 GENENTECH INC Process for preparing substituted polycyclic pyridone derivative and crystal thereof
Sep, 2038

(13 years from now)

US11925648 GENENTECH INC Solid dosage form having excellent stability
Apr, 2041

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-811) Oct 16, 2022
New Chemical Entity Exclusivity(NCE) Oct 24, 2023
M(M-187) Dec 19, 2027

Drugs and Companies using BALOXAVIR MARBOXIL ingredient

NCE-1 date: 24 October, 2022

Market Authorisation Date: 23 November, 2020

Treatment: Method for treating influenza; Method for post-exposure prophylaxis of influenza

Dosage: FOR SUSPENSION

How can I launch a generic of XOFLUZA before it's drug patent expiration?
More Information on Dosage

XOFLUZA family patents

Family Patents

38. Yutrepia patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10898494 LIQUIDIA TECH Dry powder treprostinil for the treatment of pulmonary hypertension
May, 2037

(11 years from now)

US11660304 LIQUIDIA TECH Dry powder treprostinil for the treatment of pulmonary hypertension
May, 2037

(11 years from now)

US11712442 LIQUIDIA TECH Dry powder treprostinil for the treatment of pulmonary hypertension
May, 2037

(11 years from now)

US11744835 LIQUIDIA TECH Dry powder treprostinil for the treatment of pulmonary hypertension
May, 2037

(11 years from now)

US11744836 LIQUIDIA TECH Dry powder treprostinil for the treatment of pulmonary hypertension
May, 2037

(11 years from now)




Drugs and Companies using TREPROSTINIL SODIUM ingredient

Market Authorisation Date: 23 May, 2025

Treatment: Method of treating pulmonary arterial hypertension or pulmonary hypertension associated with interstitial disease by administering treprostinil or a salt thereof by using an inhalation device; Definit...

Dosage: POWDER

More Information on Dosage

YUTREPIA family patents

Family Patents

39. Zepzelca patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12324806 JAZZ Method of treating SCLC and managing hepatotoxicity
May, 2040

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 15, 2025
Orphan Drug Exclusivity(ODE-304) Jun 15, 2027

Drugs and Companies using LURBINECTEDIN ingredient

NCE-1 date: 15 June, 2024

Market Authorisation Date: 15 June, 2020

Treatment: Treating metastatic sclc after platinum chemotherapy with lurbinectedin monotherapy by reducing the dose for grade ≥3 hepatotoxicity from 3.2 to 2.6 mg/m2 and 2.6 to 2.0 mg/m2 lurbinectedin within 35 ...

Dosage: POWDER

More Information on Dosage

ZEPZELCA family patents

Family Patents

40. Zoryve patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12310956 ARCUTIS Topical roflumilast formulation having improved delivery and plasma half-life
Jun, 2037

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 15, 2026
New Patient Population(NPP) Oct 05, 2026
New Strength(NS) Jul 09, 2027

Drugs and Companies using ROFLUMILAST ingredient

Market Authorisation Date: 09 July, 2024

Treatment: Topical treatment of plaque psoriasis of the scalp and body in patients 12 years of age and older

Dosage: FOAM; CREAM

More Information on Dosage

ZORYVE family patents

Family Patents